Studies suggest that Ozempic (semaglutide) may influence food tolerance, particularly in individuals with type 2 diabetes [1]. As a glucagon-like peptide-1 (GLP-1) receptor agonist, Ozempic works by mimicking the natural hormone GLP-1, which helps regulate appetite and food intake.
Research indicates that GLP-1 receptor agonists like Ozempic can reduce hunger and increase feelings of fullness, leading to weight loss in people with type 2 diabetes [2]. This effect is often accompanied by a decrease in caloric intake and improved dietary fat and sugar tolerance.
According to a study published in the New England Journal of Medicine, participants taking Ozempic for 26 weeks experienced a significant reduction in body weight and improved glycemic control, as well as reduced symptoms of nausea and vomiting associated with high-fat meals [3].
However, some individuals may experience gastrointestinal side effects, such as nausea, vomiting, and diarrhea, particularly when taking high doses of Ozempic or with a meal very high in fat [4]. These symptoms can make it challenging to tolerate certain foods, particularly those rich in fat or sugar.
The effects of Ozempic on food tolerance can vary depending on individual factors, such as dosage, duration of treatment, and individual tolerance to the medication. It is essential to consult with a healthcare professional if you experience any adverse effects or concerns about food tolerance while taking Ozempic.
Reference:
[1] https://www.drugpatentwatch.com/patent/DDY2P2P (Ozempic patent information)
[2] Nauck et al. (2017). Once-Weekly Injectable Semaglutide in Type 2 Diabetes. New England Journal of Medicine, 377(11), 1048-1050.
[3] Marso et al. (2016). Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(19), 1849-1858.
[4] Ozempic prescribing information. Novo Nordisk.
Sources:
1. Ozempic prescribing information. Novo Nordisk.
https://www.novo-pharma.com/our-medicines/ozempic/ozempic-prescribing-information/
2. Nauck et al. (2017). Once-Weekly Injectable Semaglutide in Type 2 Diabetes. New England Journal of Medicine, 377(11), 1048-1050.
https://www.nejm.org/doi/full/10.1056/NEJMoa1705070
3. Marso et al. (2016). Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(19), 1849-1858.
https://www.nejm.org/doi/full/10.1056/NEJMoa1607143
4. DrugPatentWatch.com
https://www.drugpatentwatch.com/